Literature DB >> 27146499

[Response of BRAF(L597Q)-mutant melanoma to trametinib : Targeted melanoma therapy beyond BRAF(V600) mutations].

O Haase1, O Angün2, V Grätz2, N Lüttmann2, A Neumann3, D Zillikens2, P Terheyden2.   

Abstract

Approximately 7 % of melanomas have a BRAF mutation beyond codon 600. These mutations can be BRAF activating without being addressable by an approved BRAF inhibitor. The case of a patient with fulminant metastatic melanoma and a BRAF(L597Q) mutation is presented. It is demonstrated that the tumor shows an excellent response to the MEK inhibitor trametinib. This is an example for possible targeted therapy in a non-V600-mutated melanoma resulting in a 17-month overall survival.

Entities:  

Keywords:  BRAF inhibitor; MEK inhibitor; Survival; Toxicity; Tumor

Mesh：

Substances：

Year:  2016        PMID： 27146499     DOI： 10.1007/s00105-016-3785-3

Source DB:  PubMed          Journal:  Hautarzt        ISSN： 0017-8470            Impact factor:   0.751


  8 in total

1.  Improved survival with MEK inhibition in BRAF-mutated melanoma.

Authors:  Keith T Flaherty; Caroline Robert; Peter Hersey; Paul Nathan; Claus Garbe; Mohammed Milhem; Lev V Demidov; Jessica C Hassel; Piotr Rutkowski; Peter Mohr; Reinhard Dummer; Uwe Trefzer; James M G Larkin; Jochen Utikal; Brigitte Dreno; Marta Nyakas; Mark R Middleton; Jürgen C Becker; Michelle Casey; Laurie J Sherman; Frank S Wu; Daniele Ouellet; Anne-Marie Martin; Kiran Patel; Dirk Schadendorf
Journal:  N Engl J Med       Date:  2012-06-04       Impact factor: 91.245

2.  Major clinical response to a BRAF inhibitor in a patient with a BRAF L597R-mutated melanoma.

Authors:  Philippe Bahadoran; Maryline Allegra; Florence Le Duff; Elodie Long-Mira; Paul Hofman; Damien Giacchero; Thierry Passeron; Jean-Philippe Lacour; Robert Ballotti
Journal:  J Clin Oncol       Date:  2013-05-28       Impact factor: 44.544

3.  Distinct sets of genetic alterations in melanoma.

Authors:  John A Curtin; Jane Fridlyand; Toshiro Kageshita; Hetal N Patel; Klaus J Busam; Heinz Kutzner; Kwang-Hyun Cho; Setsuya Aiba; Eva-Bettina Bröcker; Philip E LeBoit; Dan Pinkel; Boris C Bastian
Journal:  N Engl J Med       Date:  2005-11-17       Impact factor: 91.245

4.  Dabrafenib in patients with melanoma, untreated brain metastases, and other solid tumours: a phase 1 dose-escalation trial.

Authors:  Gerald S Falchook; Georgina V Long; Razelle Kurzrock; Kevin B Kim; Tobias H Arkenau; Michael P Brown; Omid Hamid; Jeffrey R Infante; Michael Millward; Anna C Pavlick; Steven J O'Day; Samuel C Blackman; C Martin Curtis; Peter Lebowitz; Bo Ma; Daniele Ouellet; Richard F Kefford
Journal:  Lancet       Date:  2012-05-19       Impact factor: 79.321

5.  Genomic Classification of Cutaneous Melanoma.

Authors: 
Journal:  Cell       Date:  2015-06-18       Impact factor: 41.582

6.  Activity of trametinib in K601E and L597Q BRAF mutation-positive metastatic melanoma.

Authors:  Samantha E Bowyer; Aparna D Rao; Megan Lyle; Shahneen Sandhu; Georgina V Long; Grant A McArthur; Jeanette M Raleigh; Rodney J Hicks; Michael Millward
Journal:  Melanoma Res       Date:  2014-10       Impact factor: 3.599

7.  BRAF(L597) mutations in melanoma are associated with sensitivity to MEK inhibitors.

Authors:  Kimberly Brown Dahlman; Junfeng Xia; Katherine Hutchinson; Charles Ng; Donald Hucks; Peilin Jia; Mohammad Atefi; Zengliu Su; Suzanne Branch; Pamela L Lyle; Donna J Hicks; Viviana Bozon; John A Glaspy; Neal Rosen; David B Solit; James L Netterville; Cindy L Vnencak-Jones; Jeffrey A Sosman; Antoni Ribas; Zhongming Zhao; William Pao
Journal:  Cancer Discov       Date:  2012-07-13       Impact factor: 39.397

8.  Beyond BRAF(V600): clinical mutation panel testing by next-generation sequencing in advanced melanoma.

Authors:  Alan E Siroy; Genevieve M Boland; Denái R Milton; Jason Roszik; Silva Frankian; Jared Malke; Lauren Haydu; Victor G Prieto; Michael Tetzlaff; Doina Ivan; Wei-Lien Wang; Carlos Torres-Cabala; Jonathan Curry; Sinchita Roy-Chowdhuri; Russell Broaddus; Asif Rashid; John Stewart; Jeffrey E Gershenwald; Rodabe N Amaria; Sapna P Patel; Nicholas E Papadopoulos; Agop Bedikian; Wen-Jen Hwu; Patrick Hwu; Adi Diab; Scott E Woodman; Kenneth D Aldape; Rajyalakshmi Luthra; Keyur P Patel; Kenna R Shaw; Gordon B Mills; John Mendelsohn; Funda Meric-Bernstam; Kevin B Kim; Mark J Routbort; Alexander J Lazar; Michael A Davies
Journal:  J Invest Dermatol       Date:  2014-08-22       Impact factor: 8.551
  8 in total
  1 in total

Review 1.  Classifying BRAF alterations in cancer: new rational therapeutic strategies for actionable mutations.

Authors:  Matthew Dankner; April A N Rose; Shivshankari Rajkumar; Peter M Siegel; Ian R Watson
Journal:  Oncogene       Date:  2018-03-15       Impact factor: 9.867
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.